Physiological and biochemical activities are basically the result of identification, interaction and balance between protein ... peptide bank? Finding a leading epitope peptide is the key for drug ...

PRISM BioLab & Elix join forces to speed up AI-driven drug discovery for protein-protein interaction targets: Tokyo, Japan Tuesday, April 15, 2025, 16:00 Hrs [IST] PRISM BioLab, C ...

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceu tical Co.

Elix Inc. has entered into a drug discovery collaboration with Prism Biolab Co. Ltd. to accelerate AI-driven drug discovery for challenging protein-protein interaction targets. The partnership will ...

Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking ...

This enzymatic method enables highly specific and complete 1:1 protein conjugations with small molecules, solid supports, and other proteins, offering broad applicability across diverse biochemical ...

PRISM BioLab , today announced that it has entered into a drug discovery collaboration with Elix, effective April 1, 2025.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

The award will be presented at the 2025 Protein and Peptide Science Group Early Stage Researcher Meeting ... the study of protein-protein interaction inhibitors and the chemical proteomic de novo ...

For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously undruggable cancer protein target ... designed a peptide inhibitor that binds ...

A team from the University of Bath has developed peptides capable of permanently blocking the cJun protein, which is involved ...